Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

ZacksResearch Jan. 29 at 6:00 AM

$JNJ just beat Q4 — but the real question is whether this rally has legs. 👀 The company topped Q4 expectations and guided 2026 sales to $100–$101B, with Innovative Medicine and MedTech growth helping offset the Stelara LOE. A steady setup, but worth a closer look. Should you stay invested? Full breakdown here 👉 https://www.zacks.com/stock/news/2824501/should-you-stay-invested-in-jj-stock-after-q4-beat-solid-guidance?cid=sm-stocktwits-2-2824501-teaser-30688&ADID=SYND_STOCKTWITS_TWEET_2_2824501_TEASER_30688

0 · Reply

Quantumup Jan. 28 at 9:41 PM

Raymond James⬆️ $TYRA's PT to $55 from $35 and reiterated at Strong Buy. $URGN $JNJ $PFE $MRK ALPMY Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2016625267691683922?s=20

0 · Reply

clan Jan. 28 at 6:53 PM

$JNJ $GILD $CIPLA.NSE Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No more shooting up at meals for diabetics!❤️

0 · Reply

FRAGMENTS Jan. 28 at 6:51 PM

$PDYN $UNH $ABBV $JNJ

0 · Reply

ZacksResearch Jan. 28 at 5:03 PM

0 · Reply

DavidFloydTrader Jan. 28 at 4:26 PM

We don’t take swing trades without market context. If equity indices aren’t aligned, individual stock setups don’t matter. In early January, they were. $JNJ qualified. Plan defined. Execution complete.

0 · Reply

3DBuilds Jan. 28 at 4:04 PM

$NTLA $BEAM $JNJ $REGN $BMY The Future is here People 💯 💰 🌎

0 · Reply

ZacksResearch Jan. 28 at 4:03 PM

$JNJ defies expectations with strong Q4 results! 📈 Revenues surged 9.1% to $24.56B, and adjusted EPS jumped 20.6% YoY. The company’s 2026 guidance is bullish, with sales expected to hit $100-$101B. 🚀 See why staying invested could be wise 👉 https://www.zacks.com/stock/news/2824501/should-you-stay-invested-in-jj-stock-after-q4-beat-solid-guidance?cid=sm-stocktwits-2-2824501-body-30687&ADID=SYND_STOCKTWITS_TWEET_2_2824501_BODY_30687

0 · Reply

ripster47 Jan. 28 at 2:46 PM

$JNJ | Morgan Stanley Upgrades Johnson & Johnson to Overweight with $262 Price Target Morgan Stanley upgrades Johnson & Johnson, citing a strong product cycle in Biopharma and higher confidence in the company's growth outlook. For More Research and Insight Follow Tenet Research https://x.com/tenet_research

0 · Reply

TheStockTraderHub Jan. 28 at 2:19 PM

Wednesday’s biggest analyst calls: Mizuho upgrades Applied Materials to outperform from neutral Morgan Stanley upgrades Johnson & Johnson to overweight from equal weight Rothschild & Co Redburn upgrades Visa to buy from neutral Wedbush reiterates Apple as outperform Oppenheimer names Amazon a top pick $AMAT $JNJ $V $AAPL $AMZN

0 · Reply

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 1 day ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 1 day ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 3 days ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 7 days ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 7 days ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 7 days ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 7 days ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 7 days ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 7 days ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 7 days ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 7 days ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 7 days ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 7 days ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 8 days ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 8 days ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 9 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 10 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 14 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 15 days ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 16 days ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 16 days ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 16 days ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 17 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 18 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 18 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 19 days ago

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 5:10 AM EST - 20 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 20 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 8:43 PM EST - 20 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:24 PM EST - 20 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 7, 2026, 8:00 AM EST - 21 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 6, 2026, 8:03 AM EST - 22 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

$Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma$

Jan 6, 2026, 6:52 AM EST - 22 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 2, 2026, 5:06 PM EST - 26 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Jan 2, 2026, 4:17 PM EST - 26 days ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Jan 2, 2026, 8:00 AM EST - 26 days ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Dec 31, 2025, 8:47 AM EST - 4 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 30, 2025, 1:31 PM EST - 4 weeks ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Dec 30, 2025, 9:55 AM EST - 4 weeks ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 5:05 AM EST - 4 weeks ago

More Upside For JNJ Stock In 2026?

Dec 29, 2025, 1:56 PM EST - 4 weeks ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Dec 29, 2025, 8:00 AM EST - 4 weeks ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 28, 2025, 6:44 AM EST - 4 weeks ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Dec 26, 2025, 8:13 AM EST - 4 weeks ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 23, 2025, 11:41 AM EST - 5 weeks ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 12:34 AM EST - 5 weeks ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 22, 2025, 11:15 PM EST - 5 weeks ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 20, 2025, 3:55 AM EST - 5 weeks ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 5 weeks ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

ZacksResearch Jan. 29 at 6:00 AM

0 · Reply

Quantumup Jan. 28 at 9:41 PM

0 · Reply

clan Jan. 28 at 6:53 PM

$JNJ $GILD $CIPLA.NSE Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No more shooting up at meals for diabetics!❤️

0 · Reply

FRAGMENTS Jan. 28 at 6:51 PM

$PDYN $UNH $ABBV $JNJ

0 · Reply

ZacksResearch Jan. 28 at 5:03 PM

0 · Reply

DavidFloydTrader Jan. 28 at 4:26 PM

0 · Reply

3DBuilds Jan. 28 at 4:04 PM

$NTLA $BEAM $JNJ $REGN $BMY The Future is here People 💯 💰 🌎

0 · Reply

ZacksResearch Jan. 28 at 4:03 PM

0 · Reply

ripster47 Jan. 28 at 2:46 PM

0 · Reply

TheStockTraderHub Jan. 28 at 2:19 PM

0 · Reply

FRAGMENTS Jan. 28 at 1:38 PM

$PDYN Orion Properties (ONL). This piece explains what’s happening right now: the buyout headlines, the strategic review, and the refinancing timeline that will drive the next moves. It’s a simple walkthrough of what matters, what to watch in filings, and what could change the outcome. HERE:https://cundilldeepvalue.substack.com/p/orion-properties-onl-permission-required $UNH $ABBV $JNJ

0 · Reply

anachartanalyst Jan. 28 at 12:01 PM

$JNJ https://anachart.com/wp-content/uploads/ana_temp/1769601680_soc-img.jpg

0 · Reply

erevnon Jan. 28 at 11:47 AM

Morgan Stanley upgrades Johnson & Johnson $JNJ from Equal-Weight to Overweight and raises the price target from $200 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

theflynews Jan. 28 at 10:02 AM

Johnson &amp; Johnson just upgraded at Morgan Stanley, here's why - $JNJ - https://legacy.thefly.com/permalinks/entry.php/JNJid4278898?1769

0 · Reply

houthis4justice Jan. 27 at 11:28 PM

$EBAY $CCL $JNJ $AAPL MUST SEE!!!!! https://youtu.be/pQ0jKNJ6SYw

0 · Reply

StocktwitsNews Jan. 27 at 9:25 PM

JNJ Stock Rises On Fresh FDA Approval For Multiple Myeloma Drug $JNJ $QUSA $JGRO https://stocktwits.com/news/equity/markets/jnj-stock-rises-on-fresh-fda-approval-for-multiple-myeloma-drug/cmyOB6UR4id

0 · Reply

Traidn Jan. 27 at 9:17 PM

$JNJ 🚨 https://www.express.co.uk/news/world/2162841/airports-covid-style-horror-bat-virus

0 · Reply

GreenEnergy2022 Jan. 27 at 8:36 PM

$ALT Best in class. Science dont lie "These are industry leading results, compared to a cT1 reduction of 110ms with 15mg tirzepatide at 52 weeks. A cT1 reduction of 88ms is clinically significant for MASH resolution" $MRK $ABBV $JNJ

0 · Reply

Sunny3999 Jan. 27 at 5:23 PM

$PMN break $10 and will see 12 this week $ABBV $CELG $JNJ $PFE

0 · Reply

ZacksResearch Jan. 27 at 4:52 PM

$JNJ is aiming BIG — $100B+ sales by 2026. 🚀 Is the growth engine stronger than the patent risks? Management is targeting $100–$101B in 2026 sales, projecting faster growth in both Innovative Medicine and MedTech — even with looming patent losses in the background. See how J&J plans to hit these numbers 👉 https://www.zacks.com/stock/news/2823561/jj-targets-100b-sales-in-2026-as-growth-accelerates-in-both-units?cid=sm-stocktwits-2-2823561-teaser-30457&ADID=SYND_STOCKTWITS_TWEET_2_2823561_TEASER_30457

0 · Reply

Deeznutsswapmeet Jan. 27 at 3:58 PM

$JNJ Please someone make sure to tell @Suite510 that he’s an idiot for whatever dumbass take he posts today!

0 · Reply

ZacksResearch Jan. 27 at 3:52 PM

$JNJ sets bullish 2026 outlook despite looming generic threats! 🚀 🔹 2026 sales forecast: $100B-$101B, beating the $98.5B consensus 🔹 2026 Innovative Medicine & MedTech segments expected to accelerate 🔹 New drug launches expected to help drive growth despite more pronounced impact of patent expirations like Stelara in 2026 J&J’s strategic moves could drive growth. See the full analysis here 👉 https://www.zacks.com/stock/news/2823561/jj-targets-100b-sales-in-2026-as-growth-accelerates-in-both-units?cid=sm-stocktwits-2-2823561-body-30456&ADID=SYND_STOCKTWITS_TWEET_2_2823561_BODY_30456

0 · Reply

Market Cap	540.74B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	20.51
Forward PE	19.21
Profit Margin	28.46%
Debt to Equity Ratio	0.50

Volume	9,026,495
Avg Vol	9,150,810
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	95%
Beta	0.34
Analysts	Strong Sell
Price Target	$226.36